TELDRIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TELDRIN (TELDRIN).
TELDRIN contains loratadine and pseudoephedrine. Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
| Metabolism | Loratadine is extensively metabolized in the liver by CYP3A4 and CYP2D6 to its active metabolite desloratadine. Pseudoephedrine is partially metabolized in the liver by N-demethylation to inactive metabolites; about 55-75% is excreted unchanged in urine. |
| Excretion | Renal: 55-60% unchanged; fecal: 35-40%; minor biliary elimination. |
| Half-life | Terminal half-life: 9-12 hours (range 8-14) in healthy adults; prolonged in renal impairment. |
| Protein binding | 90-95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 5-8 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism. |
| Onset of Action | Oral: 1-2 hours; intravenous: 10-15 minutes. |
| Duration of Action | 6-8 hours for symptom relief; extended up to 12 hours at higher doses. |
1-2 mg orally twice daily; maximum 4 mg/day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 30-50 mL/min: 1 mg twice daily; GFR <30 mL/min: 1 mg once daily. |
| Liver impairment | Child-Pugh A: 1 mg twice daily; Child-Pugh B or C: 1 mg once daily. |
| Pediatric use | For children ≥6 years: 0.05 mg/kg/day divided every 12 hours; maximum 2 mg/day. |
| Geriatric use | Initiate at 1 mg once daily; increase cautiously; monitor for sedation and anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TELDRIN (TELDRIN).
| Breastfeeding | Excreted in breast milk; M/P ratio 0.5–1.0. Due to potential for irritability or sedation in infant, caution advised. Use only if clearly needed. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities (cleft palate, skeletal malformations) at high doses; human data limited, risk cannot be excluded. Second/third trimester: No known teratogenicity, but may cause uterine contraction suppression or neonatal irritability if used near term. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Concurrent use or recent use (within 14 days) of monoamine oxidase inhibitors (MAOIs)","Severe hypertension or coronary artery disease","Narrow-angle glaucoma","Urinary retention","Hypersensitivity to loratadine, pseudoephedrine, or any component of the formulation"]
| Precautions | ["Severe hypertension and cardiovascular events: Use with caution in patients with hypertension, ischemic heart disease, arrhythmias, or other cardiovascular conditions.","Increased intraocular pressure: Use caution in patients with narrow-angle glaucoma.","Urinary retention: Use caution in patients with prostatic hypertrophy or other urinary obstructive disorders.","Endocrine disorders: Use caution in patients with hyperthyroidism or diabetes mellitus.","Central nervous system effects: Insomnia, dizziness, or nervousness may occur, especially with higher doses.","Drug interactions: Avoid concurrent use with MAOIs or within 14 days of discontinuation; use caution with other sympathomimetics, antihypertensives, or beta-blockers."] |
Loading safety data…
| Maternal: Blood pressure, heart rate, uterine activity; monitor for signs of hypersensitivity. Fetal: Heart rate monitoring if used in labor; consider nonstress test for prolonged use. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies show no impairment at therapeutic doses. |